bis<3-(bromomethyl)phenyl> ether | 69484-03-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: bis<3-(bromomethyl)phenyl> ether
• 英文别名: 3,3'-oxybis((bromomethyl)benzene)；3,3'oxybis(bromomethyl)benzene；3,3'-Bis(bromomethyl)diphenylaether；1-(Bromomethyl)-3-[3-(bromomethyl)phenoxy]benzene
• CAS: 69484-03-3
• 化学式: C₁₄H₁₂Br₂O
• 分子量: 356.057
• InChiKey: USHUUQWGHNOWOP-UHFFFAOYSA-N

物化性质

• 熔点：
  87 °C(Solv: heptane (142-82-5))
• 沸点：
  402.0±40.0 °C(Predicted)
• 密度：
  1.625±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  bis<3-(bromomethyl)phenyl> ether 在 氢氧化钾 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 乙醇 、 正庚烷 、 乙基苯 为溶剂， 反应 4.67h， 生成 3-{3-[3-(2-Carboxy-2-methyl-propyl)-phenoxy]-phenyl}-2,2-dimethyl-propionic acid
  参考文献：
  名称：

  Long Hydrocarbon Chain Ether Diols and Ether Diacids That Favorably Alter Lipid Disorders in Vivo

  摘要：

  Long hydrocarbon chain ethers with bis-terminal hydroxyl or carboxyl groups have been synthesized and evaluated for their potential to favorably alter lipid disorders including metabolic syndrome. Compounds were assessed for their effects on the de novo incorporation of radiolabeled acetate into lipids in primary cultures of rat hepatocytes as well as for their effects on lipid and glycemic variables in female obese Zucker fatty rats following 1 and 2 weeks of daily oral administration. The most active compounds were found to be symmetrical with four to five methylene groups separating the central ether functionality and the gem dimethyl or methyl/aryl substituents. Biological activity was found to be greatest for tetramethyl-substituted ether diols (e.g., 28 and 31), while bis(arylmethyl) derivatives (e.g., 10, 11, and 27), diethers (e.g., 49, 50, and 56), and diphenyl ethers (e.g., 35 and 36) were the least active. For the most biologically active compound 28, we observed as much as a 346% increase in serum HDL-cholesterol and a 71% reduction in serum triglycerides at the highest dose administered (100 mg/kg) after 2 weeks of treatment. For compound 31 we observed a 69% reduction in non-HDL-cholesterol, accompanied by a 131% increase in HDL-cholesterol and an 84% reduction in serum triglycerides under the same treatment conditions.

  DOI：

  10.1021/jm0400395
• 作为产物：
  描述：

  二-间甲苯基醚 在 N-溴代丁二酰亚胺(NBS) 、 过氧化苯甲酰 作用下， 以 四氯化碳 为溶剂， 反应 7.0h， 以63%的产率得到bis<3-(bromomethyl)phenyl> ether
  参考文献：
  名称：

  Through-space Electrostatic Interaction between the Electron-donating 1,3-Diphosphacyclobutane-2,4-diyl Units

  摘要：

  Catenation of stable 1,3-diphopsphacyclobutane-2,4-diyl units with biphenyl-, diphenyl ether-, and diphenylmethane-based bridging groups were utilized for evaluation of the distinct through-space interaction between the electron-donating P-heterocyclic biradical chromophores. Structural properties of the oligo(biradicals), characterized by X-ray crystallography and DFT calculation, suggest a possible distance between the biradical units for the through-space interaction.

  DOI：

  10.1021/ol401456h

文献信息

• Nickel(II), palladium(II) and platinum(II) complexes of trans spanning ditertiary phosphine 3,3′-oxybis- [(di-meta-tolylphosphino)methyl]benzene
  作者：Pramesh N. Kapoor

  DOI：10.1016/0022-328x(86)80458-2

  日期：1986.11

  The synthesis of the trans-spanning bidentate diphosphine ligand, 3,3′-oxybis-(di-meta-tolylphosphino)methyl]benzene (I) and its complexes with NiII, PdII and PtII are described. The ligand I forms monomeric trans square planar complexes [MX2(I)] (M = Ni, Pd or Pt, X = Cl or X = NCS in case of Ni). 31P and 1H NMR parameters are reported.

  描述了跨跨的二齿二膦配体，3，3'-氧双-（二-间甲苯基膦基）甲基]苯（I）及其与Ni II，Pd II和Pt II的配合物的合成。配体I形成单体反式方形平面络合物[MX 2（I）]（对于Ni，M ＝ Ni，Pd或Pt，X ＝ Cl或X ＝ NCS）。报告了31 P和1 H NMR参数。
• [EN] ETHER COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES<br/>[FR] COMPOSES D'ETHER ET COMPOSITIONS POUR LE CONTROLE DE CHOLESTEROL ET UTILISATIONS ASSOCIEES
  申请人：ESPERION THERAPEUTICS INC

  公开号：WO2005068410A1

  公开（公告）日：2005-07-28

  The present invention relates to novel ether compounds, compositions comprising ether compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising an ether compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

  本发明涉及新型醚化合物、包含醚化合物的组合物以及用于治疗和预防心血管疾病、血脂异常、蛋白异常和葡萄糖代谢紊乱的方法，包括给予含有醚化合物的组合物。该发明的化合物、组合物和方法还可用于治疗和预防阿尔茨海默病、X综合征、过氧化物酶体增殖激活受体相关疾病、败血症、血栓性疾病、肥胖、胰腺炎、高血压、肾脏疾病、癌症、炎症和阳痿。在某些实施方式中，该发明的化合物、组合物和方法可与其他治疗药物（如降胆固醇和降血糖药物）联合治疗时使用。
• Transition metal complexes of the trans-spanning ditertiary phosphine, bis{3-[bis(3-trifluoromethylphenyl)- phosphinomethyl]phenyl} ether
  作者：Pramesh N. Kapoor

  DOI：10.1016/0022-328x(88)89090-9

  日期：1988.3

  The bidentate ditertiaryphosphine ligand, bis3-[bis(3-trifluoromethylphenyl) phosphinomethyl]phenyl} ether (LL) forms monomeric trans-square planar complexes [MX2(LL)] (M = Ni, Pd or Pt, X = Cl; M = Ni, X = NCS) as well as trans-[PtHCl(LL)]; 31P and 1H NMR, and selected IR parameters are reported.

  双齿二叔膦配体双3- [双（3-（三（三氟甲基苯基）膦基甲基]苯基}）醚（LL）形成单体反方形平面络合物[MX 2（LL）]（M = Ni，Pd或Pt ，X ＝ Cl； M ＝ Ni，X ＝ NCS）以及反式-[PtHCl（LL）]；报告了31 P和1 H NMR，以及选定的IR参数。